Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-010391 in KRAS G12D Mutant Advanced Solid Tumors
NCT07624214Phase 1Not yet recruiting
- Sponsor
- Leadingtac
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LT-010391 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more, sponsored by Leadingtac. Primary endpoints: Adverse Events at 2 years and Dose Limiting Toxicities at 21 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
LT-010391
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07624214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624214.